AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29893482 — intervention group
Group type: COMPARATOR
Intervention: Active distraction arm (robot dancing and singing)
Number of subjects: 40
Study 26659384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl injection
Number of subjects: 8
Study 26659384 — intervention group
Group type: COMPARATOR
Intervention: Control (Normotensive men)
Number of subjects: 8
Study 25149384 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinxieling decoction (8 weeks treatment)
Number of subjects: 120
Study 25149384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 weeks treatment)
Number of subjects: 120
Study 23129602 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 350 mg
Number of subjects: 168
Study 23129602 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 420 mg
Number of subjects: 168
Study 23129602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 20826719 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 600
Study 20826719 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 600
Study 18093356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 126
Study 18093356 — intervention group
Group type: COMPARATOR
Intervention: No bispectral index monitoring
Number of subjects: 126
Study 16022920 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/(m² day) IV days 1-5, cisplatin 50 mg/m² IV day 5 (T/C)
Number of subjects: 82
Study 16022920 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/(m² day) IV days 1-5, etoposide 60 mg/(m² day) IV days 1-5 (T/E)
Number of subjects: 82
Study 12675729 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of elemental Fe per day
Number of subjects: 100
Study 12675729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11199506 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE III inhibitor (amrinone, 1 mg/kg)
Number of subjects: 16
Study 11199506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PDE III inhibitor)
Number of subjects: 16
Study 8887212 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min of self-selected exercise in a student gymnasium
Number of subjects: 17
Study 8887212 — intervention group
Group type: COMPARATOR
Intervention: 20 min of rest in a neutral setting (laboratory)
Number of subjects: 17
Study 1728484 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amrinone
Number of subjects: 14
Study 1728484 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg digoxin (infused over 20 minutes)
Number of subjects: 14
Study 1728484 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amrinone (after digoxin infusion)
Number of subjects: 14
Study 1728484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (instead of digoxin)
Number of subjects: 14
Study 6374931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol hydrochloride 160 mg/d plus hydrochlorothiazide 25 mg/d
Number of subjects: 50
Study 6374931 — intervention group
Group type: COMPARATOR
Intervention: Reserpine 0.1 mg/d plus hydrochlorothiazide 25 mg/d
Number of subjects: 50
Study 31721757 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Obturator Nerve Block (FONB)
Number of subjects: 154
Study 31721757 — intervention group
Group type: COMPARATOR
Intervention: Fascia Iliaca Compartment Block (FICB)
Number of subjects: 154
Study 29697150 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive weights
Number of subjects: 846
Study 29697150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic weights
Number of subjects: 846
Study 29697150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of components of responsibility
Number of subjects: 846
Study 29697150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental effort, invasiveness, dexterity, experience, and knowledge
Number of subjects: 846
Study 26684472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 60
Study 26684472 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 60
Study 24615217 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive care (proactive outreach and offer of choice of smoking cessation services)
Number of subjects: 6400
Study 24615217 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6400
Study 24615217 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive care
Number of subjects: 6400
Study 22995464 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Jelly (RJ) 3000 mg in 100 ml liquid/day for 6 months
Number of subjects: 61
Study 19756814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI)
Number of subjects: 256
Study 19756814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in females
Number of subjects: 256
Study 19756814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in males
Number of subjects: 256
Study 19756814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in females with suspected primary CAD
Number of subjects: 256
Study 19756814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in females with suspected progression
Number of subjects: 256
Study 18070745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive instructor‐led intervention (ILI)
Number of subjects: 80
Study 18070745 — intervention group
Group type: COMPARATOR
Intervention: Self‐help (SH)
Number of subjects: 80
Study 16270862 — intervention group
Group type: EXPERIMENTAL
Intervention: Four different methods of travel in an immersive virtual environment (IVE)
Number of subjects: 0
Study 16270862 — intervention group
Group type: EXPERIMENTAL
Intervention: Large tracked space allowing participants to walk around the virtual environment
Number of subjects: 0
Study 16270862 — intervention group
Group type: EXPERIMENTAL
Intervention: Steed‐Usoh‐Slater Presence Questionnaire
Number of subjects: 0
Study 16270862 — intervention group
Group type: EXPERIMENTAL
Intervention: Path analysis of logged position and head orientation data
Number of subjects: 0
Study 12145577 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic CBD exploration and cholecystectomy (Group A)
Number of subjects: 78
Study 12145577 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic stone extraction and laparoscopic cholecystectomy (Group B)
Number of subjects: 78
Study 10213716 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 138
Study 10213716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 138
Study 10213716 — intervention group
Group type: COMPARATOR
Intervention: Routine perioperative care (Control)
Number of subjects: 138
Study 8544420 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone and chlorambucil
Number of subjects: 81
Study 8544420 — intervention group
Group type: COMPARATOR
Intervention: symptomatic therapy
Number of subjects: 81
Study 2364165 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal translocations (specifically t(1;19)(q23;p13)) in pre-B ALL
Number of subjects: 964
Study 2364165 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal translocations (specifically t(1;19)(q23;p13)) in early pre-B ALL
Number of subjects: 964
Study 2364165 — intervention group
Group type: EXPERIMENTAL
Intervention: t(1;19)(q23;p13) in pre-B ALL
Number of subjects: 964
Study 2364165 — intervention group
Group type: COMPARATOR
Intervention: Other translocations in pre-B ALL
Number of subjects: 964
Study 2364165 — intervention group
Group type: COMPARATOR
Intervention: Any other karyotypic abnormality in pre-B ALL
Number of subjects: 964
Study 737427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain inserted
Number of subjects: 103
Study 737427 — intervention group
Group type: COMPARATOR
Intervention: No intraperitoneal drain
Number of subjects: 103
Study 30521656 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate
Number of subjects: 56
Study 30521656 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone
Number of subjects: 56
Study 30521656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both graft materials
Number of subjects: 56
Study 30521656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 28046032 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 43
Study 28046032 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 43
Study 25511347 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl group (placebo)
Number of subjects: 60
Study 25511347 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol group
Number of subjects: 60
Study 25511347 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive paracetamol group
Number of subjects: 60
Study 23469685 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 haplotype (1236TT‐2677TT‐3435TT) carriers
Number of subjects: 12
Study 23469685 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes (AA) carriers of ABCG2 c.421C > A
Number of subjects: 12
Study 21817105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipids
Number of subjects: 102
Study 21817105 — intervention group
Group type: COMPARATOR
Intervention: Control (no intravenous lipids)
Number of subjects: 102
Study 19453924 — intervention group
Group type: COMPARATOR
Intervention: Omega-3
Number of subjects: 0
Study 19453924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16737370 — intervention group
Group type: EXPERIMENTAL
Intervention: Denial of responsibility
Number of subjects: 3
Study 16737370 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterattitudinal behavior
Number of subjects: 3
Study 12736088 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (daily oral dose of 50 mg)
Number of subjects: 15
Study 12736088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10912746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg trandolapril once daily for 6 weeks
Number of subjects: 229
Study 10912746 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan once daily for 6 weeks
Number of subjects: 229
Study 10912746 — intervention group
Group type: EXPERIMENTAL
Intervention: SBPM
Number of subjects: 229
Study 10912746 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM
Number of subjects: 229
Study 10912746 — intervention group
Group type: COMPARATOR
Intervention: Office BP
Number of subjects: 229
Study 9378688 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg q.d. at 10:00 p.m. for 12 weeks
Number of subjects: 5
Study 9378688 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin withdrawal
Number of subjects: 5
Study 9378688 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study 7691784 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy with concomitant mitomycin C
Number of subjects: 113
Study 7691784 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiation therapy alone
Number of subjects: 113
Study 3757322 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (22, 44 or 88 mEq/h)
Number of subjects: 10
Study 3757322 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl (22 or 44 mEq/h)
Number of subjects: 10
Study 3757322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water (30 mmol/h)
Number of subjects: 10
Study 3757322 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate metabolism
Number of subjects: 10
Study 31161045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced support intervention (ESI) delivered by community pharmacy team member over four months (4-6 sessions)
Number of subjects: 100
Study 31161045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced support intervention (ESI)
Number of subjects: 100
Study 31161045 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 31161045 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 100
Study 31161045 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation
Number of subjects: 100
Study 30541585 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeogo exoskeleton
Number of subjects: 29
Study 27889723 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU of oral cholecalciferol (vitamin D)
Number of subjects: 324
Study 27889723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 27889723 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 324
Study 27889723 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and Placebo
Number of subjects: 324
Study 25132872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (two doses of 15 mg/kg preoperative and postoperative)
Number of subjects: 50
Study 25132872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 50
Study 25132872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22699418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 0
Study 22699418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 0
Study 22699418 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 22699418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study 20721517 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of beta-blockers and dobutamine (Group C, n=11)
Number of subjects: 44
Study 20721517 — intervention group
Group type: COMPARATOR
Intervention: Suspension of beta-blockers to start dobutamine (Group B, n=25)
Number of subjects: 44
Study 20721517 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers used (Group A, n=8)
Number of subjects: 44
Study 18603572 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide (30 mg)
Number of subjects: 9
Study 18603572 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study 15983792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 10
Study 15983792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 10
Study 15983792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 10
Study 15983792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Number of subjects: 10
Study 15983792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11874177 — intervention group
Group type: COMPARATOR
Intervention: GH alone (Saizen, Ares‐Serono, Geneva) 18 IU/m2/week (0.2 mg/kg/week)
Number of subjects: 91
Study 11874177 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + Ox 0.1 mg/kg/day p.o.
Number of subjects: 91
Study 11874177 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + transient Ox
Number of subjects: 91
Study 9988803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 44
Study 9988803 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 44
Study 7556325 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin at 0.1, 0.25, 0.5 and 1 IU/ml added to TPN infusions
Number of subjects: 0
Study 7556325 — intervention group
Group type: COMPARATOR
Intervention: Non-heparinized control group
Number of subjects: 0
Study 2272193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flupenthixol dihydrochloride
Number of subjects: 153
Study 2272193 — intervention group
Group type: COMPARATOR
Intervention: 75 mg dothiepin hydrochloride
Number of subjects: 153
Study 7374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal L-phenylalanine (100 mM)
Number of subjects: 32
Study 7374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal L-phenylalanine
Number of subjects: 32
Study 7374100 — intervention group
Group type: COMPARATOR
Intervention: D-phenylalanine (50 mM)
Number of subjects: 32
Study 7374100 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine absorption rates
Number of subjects: 32
Study 7374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic secretion
Number of subjects: 32
Study 30845039 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instrumentation (Groups 1 and 2)
Number of subjects: 173
Study 30845039 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use patient-specific instrumentation (Group 3)
Number of subjects: 173
Study 30845039 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable patient-specific instrumentation (Groups 4 and 5)
Number of subjects: 173
Study 27941491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity sprint training with blood flow restriction (pBFR)
Number of subjects: 24
Study 27941491 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity sprint training without blood flow restriction (control group)
Number of subjects: 24
Study 25888011 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia
Number of subjects: 2601
Study 25888011 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 2601
Study 25888011 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple hypoglycemic events
Number of subjects: 2601
Study 22934971 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio-based professional development program (12 months)
Number of subjects: 73
Study 22934971 — intervention group
Group type: COMPARATOR
Intervention: Routine professional development programs (control group)
Number of subjects: 73
Study 21232979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1.2 g/d orally before and for 2 days after surgery)
Number of subjects: 40
Study 21232979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20054753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine, initial dose of 3 mg/day b.i.d., escalated to maximum tolerated dose in at least 4-week intervals.
Number of subjects: 54
Study 17926612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupuncture and medicine group (acupuncture balance points 'Jiangya' and 'Shenbing' with small dose of hypotensor, Irbesartan)
Number of subjects: 152
Study 17926612 — intervention group
Group type: COMPARATOR
Intervention: Medication group (oral administration of Irbesartan and Fosinopril)
Number of subjects: 152
Study 17926612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupuncture and medicine group
Number of subjects: 152
Study 17926612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study 15178812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) added to standard carboplatin/paclitaxel chemotherapy
Number of subjects: 0
Study 15178812 — intervention group
Group type: COMPARATOR
Intervention: Standard carboplatin/paclitaxel chemotherapy alone
Number of subjects: 0
Study 15178812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy in patients with nonsquamous histologies
Number of subjects: 0
Study 11338198 — intervention group
Group type: EXPERIMENTAL
Intervention: Kohonen feature map (KFM) for predicting alcohol withdrawal seizures
Number of subjects: 49
Study 11338198 — intervention group
Group type: COMPARATOR
Intervention: High homocysteine (Hcy) levels on admission
Number of subjects: 49
Study 10453539 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute moderate isovolemic hemodilution
Number of subjects: 26
Study 10453539 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 7889231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous electrode polarity configuration I (RV electrode as common cathode)
Number of subjects: 21
Study 7889231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous electrode polarity configuration II (SVC electrode as common cathode)
Number of subjects: 21
Study 7889231 — intervention group
Group type: COMPARATOR
Intervention: Both configurations
Number of subjects: 21
Study 2833178 — intervention group
Group type: EXPERIMENTAL
Intervention: CE therapy (CDDP plus etoposide)
Number of subjects: 27
Study 2833178 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-AVN therapy (ACNU, VCR plus procarbazine)
Number of subjects: 27
Study 30002323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 27
Study 30002323 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 27
Study 26658268 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA + ramosetron (0.3 mg ramosetron just before anaesthesia induction, remifentanil and propofol anaesthesia)
Number of subjects: 72
Study 26658268 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 72
Study 25432143 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (TRAV)
Number of subjects: 81
Study 25432143 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost 0.01% (BIM)
Number of subjects: 81
Study 22507665 — intervention group
Group type: COMPARATOR
Intervention: 900 mg of lithium
Number of subjects: 10
Study 22507665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20446945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic BP <140 mmHg within 1 hour, maintained for up to 7 days)
Number of subjects: 2800
Study 20446945 — intervention group
Group type: COMPARATOR
Intervention: Conservative blood pressure management (target systolic BP <180 mmHg)
Number of subjects: 2800
Study 20446945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 2800
Study 18635505 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine with epidural volume extension (PBE)
Number of subjects: 88
Study 18635505 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine (PB)
Number of subjects: 88
Study 18635505 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (HB)
Number of subjects: 88